## CMB International Securities | Equity Research | Company Update



#### 招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

# Mengniu (2319 HK)

# Acquisition to access raw milk supply and become regional player

Mengniu announced to purchase 100% equity interest of Lion-Dairy & Drinks Pty Ltd, an Australian-based branded dairy and beverage company, from Kirin Foods at an initial consideration of AUD600mn (RMB2.9bn). Overall, we think the acquisition can meet Mengniu's pursuits in overseas raw milk source and distribution network in Southeast Asian market. The acquisition consideration is undemanding and there are synergies to be explored.

- Low-cost milk supply for Milk Deluxe. Australia farmgate milk price is estimated at RMB2.44/litre (RMB2.37/kg) in FY19/20E, cheaper than China's current RMB3.83/kg. After investing some modification capex, Mengniu can transfer the production of Milk Deluxe from an OEM in New Zealand (around 800,000 litres) to Lion-Dairy and can gain the OEM margin. Furthermore, Mengniu plans to raise the production volume of Milk Deluxe in Lion-Dairy to more than 200mn litres in future. These are the major synergies of the acquisition.
- Other synergies. We think there are further synergies from (1) sharing of distribution network, infrastructure and back office systems in Australia across Lion Dairy, Bellamy's and Burra Foods; (2) sharing of R&D, collaboration of sales and marketing and cross-selling across brands and products among the group. Lion-Dairy's top milk beverage brand "dare" and yogurt brand "Farmers Union" could be introduced into China and Southeast Asian markets. Mengniu can become a regional player with multi-brand portfolio in Asia Pacific.
- Room to improve margins. In FY18, Lion Dairy achieved 6.6% EBITDA margin, less than Mengniu's 7.8%. However, management targets to lift the EBITDA margin of Lion Dairy to above 10% through synergies and turnaround of white milk business (contributed around 30% of revenue but negative net profit margin).
- Undemanding valuation According to management, Lion Dairy's revenue was flat over the past 3 to 4 years given that Kirin cannot provide synergies for Lion-Dairy and Australia is a stable market. The consideration represents 13.1x historical P/E and 1x P/B. Management added that the capex required to build a new UHT plant in Australia is at least AUD300mn. Therefore, we think the consideration is undemanding. Based on FY18 results, we estimate the acquisition could enhance Mengniu's adjusted NP by 5%. The deal, subject to FIRB's approval, is expected to be completed in 1H of 2020.
- Maintain Buy. Our TP of HK\$37.00 is based on 28.0x FY20E P/E, which is the high-end of 18-30x 1-yr forward P/E range since Mengniu resumed double-digit revenue growth in FY16. Catalysts: better-than-expected revenue and margins. Risks: raw milk cost pressure (net profit drops 4% per 1% increase of raw milk price), food safety issues.

## **Earnings Summary**

(YE 31 Dec)	FY17A	FY18A	FY19E	FY20E	FY21E
Revenue (RMB mn)	60,156	68,977	79,603	78,057	87,348
YoY growth (%)	12	15	15	(2)	12
Net profit (RMB mn)	2,048	3,043	6,801	4,641	5,637
Adj. net profit (RMB mn)	2,048	3,043	3,886	4,641	5,637
Adjusted EPS (RMB)	0.526	0.779	0.993	1.179	1.433
YoY growth (%)	0	48	32	19	21
Adjusted P/E (x)	48.9	33.2	26.7	22.5	18.5
P/B (x)	4.5	3.9	3.5	3.1	2.7
Yield (%)	0.5	0.7	0.9	1.0	1.2
ROE (%)	9.4	12.7	14.1	14.5	15.6

Source: Company data, CMBIS estimates

## **BUY (Maintain)**

Target Price HK\$37.00 Up/Downside +25% Current Price HK\$29.65

## China F&B Sector

## **Albert Yip**

(852) 3900 0838 albertyip@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	116,661
Avg 3 mths t/o (HK\$ mn)	332.03
52w High/Low (HK\$)	34.60/ 22.45
Total Issued Shares (mn)	3,927.7
Source: Bloomberg	

#### **Shareholding Structure**

16.3%
9.9%
5.3%

Source: HKEx

## **Share Performance**

	Absolute	Relative
1-mth	-5.2%	-4.4%
3-mth	-10.2%	-11.6%
6-mth	1.2%	4.1%

Source: Bloomberg

## 12-mth Price Performance



Source: Bloomberg

#### **Auditor: EY**

## Related reports

"China Dairy Sector - Multiple growth drivers ahead; sector consolidation to continue" – 19 Nov 2019



## A leading player in Australia

Lion-Dairy & Drinks is a leading Australia-based branded dairy and beverage company. Its market shares in milk beverages, yogurt, juice, water ice and plant-based categories are No. 1. It is also the No. 2 player in white milk category. Lion-Dairy procures around 825mn litres of milk equivalents and 50mn kg of fresh fruit from around 280 farmers and 85 fruit growers annually. Lion-Dairy had a total of 13 manufacturing facilities (inclusive of two facilities operating as JV) and a cold chain distribution network reaching 35,000 customers in Australia.

Figure 1: Brand portfolio of Lion-Dairy & Drinks



Source: Mengniu

## **Undemanding valuation**

Kirin announced that they had commenced a sales process of Lion-Dairy in Oct 2018. According to management, Lion Dairy's revenue was flat over the past 3 to 4 years as Kirin cannot provide synergies for Lion-Dairy and Australia is a stable market. Lion Dairy recorded AUD45.8mn profit after tax (represents 7% of Mengniu's adj. net profit in FY18) in FY18 and its net assets value was AUD596mn as at 30 Aug 2019. The consideration represents 13.1x historical P/E and 1x P/B. Management added that the capex required to build a new UHT milk plant in Australia is at least AUD300mn. Therefore, we think the consideration is undemanding.

Mengniu plans to finance the acquisition 70% by internal resources and 30% by borrowing. Mengniu had RMB5.1bn cash balance as at 30 Jun 2019. After considering the RMB4.0bn cash proceeds from disposal and RMB4.2bn cash for acquisition of Bellamy, Mengniu still has RMB4.9bn internal cash to make the deal. We estimate the acquisition could enhance Mengniu's adjusted net profit by 5% based on FY18 results.

Figure 2: Historical financial results of Lion-Dairy & Drinks

YE 31 Dec (AUDmn)	FY17	FY18	Change YoY (%)
Revenue	1,779	1,756	(1)
Normalized OP	62	63	2
Profit before tax	69	66	(5)
Profit after tax	48	46	(5)
EBTIDA margin	na	6.6%	na

Source: Mengniu, Kirin



## Regulatory approvals

The completion of the deal requires the approvals by Foreign Investment Review Board of Australia as well as Australian Competition and Consumer Commission (may be waived by written consent of the purchaser and seller). Management is confident to get approval because it is a normal commercial deal and the ownership is transferred from a foreign investor to another foreign investor. The deal is expected to be completed in 1H of 2020.

## Become an integrated player in Asia Pacific

Lion Dairy has integrated capability from procurement, processing, sales and marketing to distribution. Lion-Dairy has yogurt export sales (around 2-3% of total revenue) to Asian markets with No. 1 market share in Singapore and top 5 market shares in Indonesia and Philippines (Figure 3). The combination of Lion-Dairy, Bellamy's and Burra Foods can better serve Southeast Asia and China markets. Regarding Southeast Asia market development, Mengniu will put Indonesia market as top priority and develop other countries step by step.

Figure 3: Market share of Lion-Dairy's yogurt in Southeast Asia and China



Source: Mengniu

Figure 4: CMBI estimates vs consensus

		CMBI			Consensus		Diff (%)			
US\$ mn	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	
Revenue	79,792	78,447	87,985	77,658	82,165	90,664	3%	-5%	-3%	
Gross Profit	29,703	29,711	33,584	29,321	31,418	35,002	1%	-5%	-4%	
Operating Profit	4,329	4,717	5,757	4,534	5,249	6,194	-5%	-10%	-7%	
Adjusted Net Profit	3,894	4,661	5,674	3,952	4,635	5,461	-1%	1%	4%	
Gross Margin	37.2%	37.9%	38.2%	37.8%	38.3%	38.7%	-0.6ppt	-0.4ppt	-0.5ppt	
Operating Margin	5.4%	6.0%	6.5%	5.8%	6.4%	6.8%	-0.4ppt	-0.4ppt	-0.3ppt	
Adjusted Net Margin	4.9%	5.9%	6.5%	5.1%	5.6%	6.0%	-0.2ppt	+0.3ppt	+0.5ppt	

Source: Company data, CMBIS




Figure 5: P&L

Year-end Dec 31 (RMB mn)	FY17	FY18	FY19E	FY20E	FY21E
Revenue	60,156	68,977	79,603	78,057	87,348
Liquid milk	53,015	59,389	67,910	70,058	78,701
Ice-cream	2,513	2,723	2,696	2,912	3,087
Milk powder	4,042	6,017	8,111	3,975	4,173
Others	585	848	886	1,112	1,388
Cost of sales	(38,973)	(43,193)	(49,969)	(48,492)	(54,006)
Gross profit	21,183	25,784	29,634	29,564	33,343
Other income and gains	338	635	470	374	419
Selling expenses	(14,869)	(18,833)	(21,334)	(20,841)	(23,147)
Administrative expenses	(2,497)	(2,915)	(3,423)	(3,513)	(3,931)
Other expenses	(1,182)	(936)	(1,028)	(890)	(967)
EBIT	2,972	3,734	4,320	4,694	5,717
Net finance cost	184	318	323	654	778
One-off items	0	101	3,429	0	0
Share of profit/(loss) of associates	(532)	(300)	185	246	332
Profit before tax	2,625	3,853	8,257	5,594	6,827
Income tax expense	(594)	(649)	(1,304)	(909)	(1,104)
Non-controlling interests	17	(161)	(152)	(44)	(85)
Net profit	2,048	3,043	6,801	4,641	5,637
Adjusted net profit	2,048	2,942	3,886	4,641	5,637
Adjusted EPS (Rmb)	0.53	0.75	0.99	1.18	1.43

Source: Company data, CMBIS estimates

Figure 6: P/E band chart



Source: CMBIS estimates, Bloomberg, Company data



## **Financial Summary**

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY17A	FY18A	FY19E	FY20E	FY21E	YE 31 Dec (RMB mn)	FY17A	FY18A	FY19E	FY20E	FY21E
Revenue	60,156	68,977	79,603	78,057	87,348	Profit before tax	2,625	3,853	8,257	5,594	6,827
Liquid milk	53,015	59,389	67,910	70,058	78,701	Associates & JV	532	300	(185)	(246)	(332)
Ice-cream	2,513	2,723	2,696	2,912	3,087	D&A	1,704	1,838	2,161	1,768	1,961
Milk powder	4,042	6,017	8,111	3,975	4,173	Change in working capital	1,447	1,653	1,618	861	792
Others	585	848	886	1,112	1,388	Others	(802)	(1,280)	(6,160)	(1,987)	(2,306)
Cost of sales	(38,973)	(43, 193)	(49,969)	(48,492)	(54,006)	Operating cash flow	5,505	6,363	5,692	5,990	6,941
Gross profit	21,183	25,784	29,634	29,564	33,343						
						Capex	(2,152)	(3,149)	(3,800)	(4,000)	(3,000)
Other income and gains	338	635	470	374	419	Acquisitions	(4,250)	(309)	0	0	0
Selling expenses	(14,869)	(18,833)	(21,334)	(20,841)	(23,147)	Others	(5,049)	(773)	4,271	1,078	1,202
Administration expenses	(2,497)	(2,915)	(3,423)	(3,513)	(3,931)	Investing cash flow	(11,450)	(4,232)	471	(2,922)	(1,798)
Other expenses	(1,182)	(936)	(1,028)	(890)	(967)	_					
EBIT	2,972	3,734	4,320	4,694	5,717	Change of borrowing	5,778	(383)	245	0	0
						Dividend paid	(399)	(526)	(711)	(899)	(1,067)
Finance income, net	184	318	323	654	778	Others	369	8	52	0	0
Others	0	101	3,429	0	0	Financing cash flow	5,748	(900)	(414)	(899)	(1,067)
JV & associates	(532)	(300)	185	246	332	_					
Pre-tax profit	2,625	3,853	8,257	5,594	6,827	Net change in cash	(196)	1,231	5,749	2,169	4,076
Income tax	(594)	(649)	(1,304)	(909)	(1,104)	Cash at the beginning	3,356	3,129	4,370	10,119	12,288
Less: Minority interests	17	(161)	(152)	(44)	(85)	Forex effect	(31)	10	0	0	0
Net profit	2,048	3,043	6,801	4,641	5,637	Cash at disposal groups	1	0	0	0	0
Adjusted net profit	2,048	3,043	3,886	4,641	5,637	Cash at the end	3,129	4,370	10,119	12,288	16,364
•						Time deposit	2,829	2,927	2,927	2,927	2,927
						Cash and cash equivalent	5,959	7,298	13,047	15,216	19,292

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY17A	FY18A	FY19E	FY20E	FY21E	YE 31 Dec	FY17A	FY18A	FY19E	FY20E	FY21E
Non-current assets	32,121	36,716	29,954	32,431	33,802	Sales mix (%)					
PPE	12,715	14,734	11,098	13,023	14,127	Liquid milk	88.1	86.1	85.3	89.8	90.1
Goodwill and intangible assets	6,727	6,980	6,108	6,041	5,974	Ice-cream	4.2	3.9	3.4	3.7	3.5
JV & associates	7,194	7,202	7,345	7,591	7,922	Milk powder	6.7	8.7	10.2	5.1	4.8
Others	5,485	7,800	5,403	5,776	5,779	Others	1.0	1.2	1.1	1.4	1.6
Current assets	26,018	29,741	35,257	38,738	44,106	P&L ratios (%)					
Cash	5,959	7,298	13,047	15,216	19,292	Gross margin	35.2	37.4	37.2	37.9	38.2
Pledged deposit	466	623	384	384	384	EBIT margin	4.9	5.4	5.4	6.0	6.5
Inventory	3,510	4,282	4,167	4,727	5,265	Net margin	3.4	4.4	8.5	5.9	6.5
Trade receivables	2,647	2,892	3,092	3,507	3,925	Adjusted net margin	3.4	4.4	4.9	5.9	6.5
Others	13,435	14,646	14,567	14,902	15,240	Payout ratio	22.8	23.2	23.0	23.0	23.0
Current liabilities	22,566	25,109	18,776	20,948	23,033	Balance sheet ratios					
Borrowings	7,935	6,523	1,964	1,964	1,964	Current ratio (x)	1.2	1.2	1.9	1.8	1.9
Trade payables	6,342	7,022	6,636	7,528	8,384	A/C receivables days	15	15	14	15	16
Other payables	7,324	10,889	9,524	10,804	12,033	A/C payables days	55	56	50	53	54
Others	965	675	652	652	652	Inventory days	32	33	31	33	34
						Asset turnover (x)	1.0	1.0	1.2	1.1	1.1
Non-current liabilities	8,465	10,884	11,119	11,119	11,119	Net gearing ratio (%)	30	22	(8)	(13)	(21)
Borrowings	6,015	8,192	8,493	8,493	8,493						
Deferred revenue	739	856	856	856	856	Returns (%)					
Others	1,711	1,835	1,770	1,770	1,770	Adjusted ROE	9.4	12.7	14.1	14.5	15.6
						Adjusted ROA	3.8	4.9	5.9	6.8	7.6
Total net assets	27,107	30,464	35,316	39,102	43,757						
Shareholders' equity	22,604	25,212	30,073	33,815	38,385	Per share					
Non-controlling interests	4,503	5,252	5,243	5,287	5,372	EPS (RMB)	0.53	0.78	0.99	1.18	1.43
						DPS (RMB)	0.12	0.18	0.23	0.27	0.33
						BVPS (RMB)	5.76	6.42	7.64	8.59	9.76

Source: Company data, CMBIS estimates



## **Disclosures & Disclaimers**

## **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## **CMBIS** Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

#### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

## **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

## For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

## For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.